Resumen
The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD).
This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish).
The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90.
The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50).
The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.
Idioma original | Inglés |
---|---|
Páginas (desde-hasta) | 586-595 |
Número de páginas | 10 |
Publicación | Movement Disorders Clinical Practice |
Volumen | 10 |
N.º | 4 |
DOI | |
Estado | Publicada - abr. 2023 |
Nota bibliográfica
Publisher Copyright:© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Financiación
Financiadores | Número del financiador |
---|---|
Amneal and Adamas | |
ISCIII‐FEDER | PI19/01576 |
Instituto de Salud Carlos III‐Fondo Europeo de Desarrollo Regional | |
MDS-NMS | |
National Institutes of Health | |
U.S. Department of Defense | |
CHDI Foundation | |
Teva Pharmaceutical Industries | |
AbbVie | |
Cleveland Clinic Foundation | |
International Parkinson and Movement Disorder Society | |
Sunovion | |
“la Caixa” Foundation | |
UCB | |
Consejería de Transformación Económica, Industria, Conocimiento y Universidades | PY20_00903 |
Ministerio de Economía y Competitividad | PI16/01575, PI19/0964 |
Instituto de Salud Carlos III | |
Ministerio de Ciencia e Innovación | RTC2019‐007150‐ 1 |
Horizon 2020 | |
Consejería de Salud y Familias, Junta de Andalucía | PE‐0210‐2018 |